Waters Parkerson & CO. LLC cut its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 2.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,077 shares of the biopharmaceutical company’s stock after selling 1,195 shares during the period. Waters Parkerson & CO. LLC’s holdings in Bristol-Myers Squibb were worth $2,535,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of BMY. Delphi Private Advisors LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $108,000. NuWave Investment Management LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $119,000. Horan Capital Advisors LLC. acquired a new position in shares of Bristol-Myers Squibb during the third quarter worth about $122,000. Prentiss Smith & Co. Inc. acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $143,000. Finally, Santori & Peters Inc. acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $144,000. Institutional investors own 71.49% of the company’s stock.
A number of equities analysts have recently commented on BMY shares. Morgan Stanley raised Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $51.56 to $78.00 in a research report on Thursday, February 15th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Monday, January 29th. Jefferies Group set a $70.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Friday, March 23rd. BMO Capital Markets reissued a “sell” rating and set a $52.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, January 22nd. Finally, Argus reissued a “buy” rating and set a $66.43 price objective (down from $75.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, March 21st. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $63.68.
In other news, Director Dinesh C. Paliwal acquired 4,770 shares of the firm’s stock in a transaction dated Monday, April 30th. The stock was acquired at an average cost of $52.40 per share, with a total value of $249,948.00. Following the completion of the acquisition, the director now owns 8,027 shares of the company’s stock, valued at $420,614.80. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.23% of the stock is currently owned by corporate insiders.
Shares of Bristol-Myers Squibb opened at $52.71 on Friday, according to Marketbeat.com. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.52 and a quick ratio of 1.39. The company has a market capitalization of $86.16 billion, a P/E ratio of 17.51, a price-to-earnings-growth ratio of 1.32 and a beta of 0.99. Bristol-Myers Squibb has a 52-week low of $49.96 and a 52-week high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.09. The firm had revenue of $5.19 billion during the quarter, compared to the consensus estimate of $5.25 billion. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.84 earnings per share. sell-side analysts predict that Bristol-Myers Squibb will post 3.41 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, May 1st. Investors of record on Friday, April 6th were issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date was Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.